Search results for "Margetuximab"

showing 4 items of 4 documents

Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/met…

2021

TPS264 Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care 1st-line therapy for advanced HER2+ GEJ/GC patients. M, an investigational Fc-engineered anti-HER2 mAb, targets the same HER2 epitope but with higher affinity for both 158V (high binding) and 158F (low binding) alleles of activating Fc receptor CD16A. Data suggest margetuximab coordinately enhances both innate and adaptive immunity, including antigen-specific T-cell responses to HER2. PD-1 and LAG-3 are T-cell checkpoint molecules that suppress T-cell function. Retifanlimab (also known as MGA012 or INCMGA00012) is a humanized, hinge-stabilized, IgG4 Κ anti-PD-1 mAb blocking binding of PD-L1 …

Cancer ResearchChemotherapybusiness.industrymedicine.drug_classMargetuximabmedicine.medical_treatmentAnti pd 1CancerMonoclonal antibodyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyTrastuzumabCancer researchMedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metasta…

2021

OncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologymedicine.diseaseGastroesophageal JunctionFirst line therapyOncologyInternal medicinemedicinebusinessAnnals of Oncology
researchProduct

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ g…

2020

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyInternal medicinemedicinebusinessAnnals of Oncology
researchProduct

Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER…

2020

TPS468 Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care palliative 1st-line therapy for advanced HER2+ GEJ/GC patients (pts). M, an Fc-engineered anti-HER2 mAb, targets the same HER2 epitope but with higher affinity for both 158V (high binding) and 158F (low binding) alleles of activating Fc receptor CD16A. M coordinately enhanced both innate and adaptive immunity, including antigen-specific T-cell responses to HER2. PD-1 and LAG-3 are T-cell checkpoint molecules that suppress T-cell function. MGA012 (INCMGA00012) is a humanized, hinge-stabilized, IgG4 κ anti-PD-1 mAb blocking binding of PD-L1 or PD-L2 to PD-1. MGD013 is a humanized Fc-bearing bi…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classMargetuximabmedicine.medical_treatmentAnti pd 1CancerMonoclonal antibodyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyTrastuzumabInternal medicineMedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct